Re-irradiation for locoregionally recurrent tumors of the thorax: a single-institution, retrospective study

[1]  L. Livi,et al.  Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies. , 2015, Cancer Treatment Reviews.

[2]  Corinne Faivre-Finn,et al.  High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer. , 2014, The Lancet. Oncology.

[3]  Sunita Ghosh,et al.  Thoracic reirradiation for lung cancer: a literature review and practical guide. , 2014, Annals of palliative medicine.

[4]  A. Del Conte,et al.  Clinical Investigation : Thoracic Cancer Stereotactic Body Radiation Therapy for Re-irradiation of Persistent or Recurrent Non-Small Cell Lung Cancer , 2014 .

[5]  J. Lovato,et al.  Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  Joe Y. Chang,et al.  Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  Steven F Petit,et al.  Reirradiation and stereotactic radiotherapy for tumors in the lung: dose summation and toxicity. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  E. Yorke,et al.  Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT) , 2013, Radiation oncology.

[9]  Joe Y. Chang,et al.  Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. , 2012, International journal of radiation oncology, biology, physics.

[10]  B. Loo,et al.  Stereotactic Ablative Radiotherapy for Reirradiation of Locally Recurrent Lung Tumors , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  I. Lax,et al.  Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  B. Jeremic,et al.  Chest reirradiation with external beam radiotherapy for locally recurrent non-small-cell lung cancer: a review. , 2011, International journal of radiation oncology, biology, physics.

[13]  Joe Y. Chang,et al.  Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. , 2010, International journal of radiation oncology, biology, physics.

[14]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Edward S. Kim,et al.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial , 2008, The Lancet.

[16]  Kenji Eguchi,et al.  Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. von Pawel,et al.  Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Ciuleanu,et al.  Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Lech Papiez,et al.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[21]  T. Tada,et al.  Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy , 2005, International Journal of Clinical Oncology.

[22]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Kris,et al.  Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens , 2000 .

[24]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Carmichael,et al.  Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Komaki,et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.

[27]  S. Anthony,et al.  Chemotherapy plus Radiotherapy Compared with Radiotherapy Alone in the Treatment of Locally Advanced, Unresectable, Non-Small-Cell Lung Cancer , 1996, Annals of Internal Medicine.

[28]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[29]  J P Pignon,et al.  A meta-analysis of thoracic radiotherapy for small-cell lung cancer. , 1992, The New England journal of medicine.

[30]  P. Warde,et al.  Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Melbye,et al.  Lung cancer: Retreatment of local recurrence after definitive irradiation , 1982, Cancer.

[32]  C. Perez,et al.  Comprar Perez & Brady's Principles and Practice of Radiation Oncology, 6/e | Rupert K Schmidt-Ullrich | 9781451116489 | Lippincott Williams & Wilkins , 2013 .

[33]  M. Kris,et al.  Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Pignon,et al.  Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: A meta‐analysis , 1996, Cancer.